Storage and handling
Protect from light and heat.
Protect from light and heat.
Homeopathic Antifungal Medicine
10 SUPPOSITORIES
For temporary relief of minor irritation, itching or soreness associated with Candida albicans yeast infections.
0,2 g Candida albicans 3X.
hydrogenated palm kernel glycerides, lactose.
Once daily, insert one suppository rectally at bedtime.
If symptoms persist more than a few days, contact a licensed practitioner. As with any drug, if you are pregnant or nursing a baby, seek the advice of a health care professional before taking this product.
Keep this and all other medications out of the reach of children. In case of accidental ingestion, seek professional assistance or contact a Poison Control Center immediately.
Protect from light and heat.
Do not use this product if imprinted inner blister pack is missing or broken.
Made in Germany.
Distributed by:
SANUM USA Corp.
1465 Slater Road
Ferndale, WA 98248
Manufactured By:
Sanum-Kehlbeck
GmbH & Co. KG
Rev. 05/2004
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 60681-0103-1 | 2019-10-21 | C162847 | 48780-1 | 956f9ecf-da70-621f-e053-dbdaa90a74ad | Pleo™ Alb SUPPOSITORIES 3X |
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 60681-0103-1 | Pleo Alb | 10 in 1 DOSE PACK | SUPPOSITORY | 10 | 1 | |
| 60681-0103-1 | Pleo Alb | 1 in 1 CARTON | SUPPOSITORY | 1 | 1 |
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 60681-0103 | PLEO ALB (CANDIDA ALBICANS) SUPPOSITORY [SANUM KEHLBECK GMBH & CO. KG] | 1 | Legacy NDC, 2 package rows | 20110113_124a7f43-181b-4b00-948d-f7bcceeb77c3.zip |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| candida albicans | ACTIVE INGREDIENT | 4D7G21HDBC | 1 | |
| candida albicans | ACTIVE MOIETY | 4D7G21HDBC | 1 | |
| lactose | INACTIVE INGREDIENT | J2B2A4N98G | 1 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 60681-0103 | 60681-0103-1 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| candida albicans | 4D7G21HDBC | ACTIB |
| lactose | J2B2A4N98G | IACT |
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| lactose | LACTOSE | J2B2A4N98G | CAPSULE / ORAL | 530 mg | ||
| lactose | LACTOSE | J2B2A4N98G | CONCENTRATE / ORAL | NA | ||
| lactose | LACTOSE | J2B2A4N98G | POWDER / VAGINAL | 430 mg | ||
| lactose | LACTOSE | J2B2A4N98G | SOLUTION / RECTAL | 8 %w/v | ||
| lactose | LACTOSE | J2B2A4N98G | FILM, EXTENDED RELEASE / TRANSDERMAL | 675 mg | ||
| lactose | LACTOSE | J2B2A4N98G | INJECTION, POWDER, FOR SOLUTION / INTRAMUSCULAR | 133 mg | ||
| lactose | LACTOSE | J2B2A4N98G | CAPSULE / RESPIRATORY (INHALATION) | 44.4 mg | ||
| lactose | LACTOSE | J2B2A4N98G | CAPSULE, COATED PELLETS / ORAL | 135.2 mg | ||
| lactose | LACTOSE | J2B2A4N98G | INJECTION, SOLUTION / INTRAVENOUS | 0.45 %w/v | ||
| lactose | LACTOSE | J2B2A4N98G | GRANULE, FOR SUSPENSION / ORAL | 512.5 mg/5ml | ||
| lactose | LACTOSE | J2B2A4N98G | TABLET, DELAYED RELEASE / ORAL | 160 mg | ||
| lactose | LACTOSE | J2B2A4N98G | SOLUTION / ORAL | 1682 mg/15ml | ||
| lactose | LACTOSE | J2B2A4N98G | CAPSULE, DELAYED RELEASE / ORAL | 231.84 mg | ||
| lactose | LACTOSE | J2B2A4N98G | TABLET / SUBLINGUAL | 352 mg | ||
| lactose | LACTOSE | J2B2A4N98G | POWDER, FOR SOLUTION / ORAL | NA | ||
| lactose | LACTOSE | J2B2A4N98G | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRACAVITARY | 193.8 mg | ||
| lactose | LACTOSE | J2B2A4N98G | TABLET / RECTAL | 20 mg | ||
| lactose | LACTOSE | J2B2A4N98G | TABLET / BUCCAL | 296.7 mg | ||
| lactose | LACTOSE | J2B2A4N98G | INJECTION / INTRAMUSCULAR | 203.5 mg | ||
| lactose | LACTOSE | J2B2A4N98G | INJECTION, POWDER, FOR SOLUTION / INTRAVENOUS | 133 mg | ||
| lactose | LACTOSE | J2B2A4N98G | TABLET, FILM COATED / ORAL | 590 mg | ||
| lactose | LACTOSE | J2B2A4N98G | SUPPOSITORY / VAGINAL | NA | ||
| lactose | LACTOSE | J2B2A4N98G | TABLET, CHEWABLE / ORAL | 1412 mg | ||
| lactose | LACTOSE | J2B2A4N98G | TABLET / ORAL | 2500 mg | ||
| lactose | LACTOSE | J2B2A4N98G | TABLET, EXTENDED RELEASE / ORAL | 400 mg | ||
| lactose | LACTOSE | J2B2A4N98G | POWDER / RESPIRATORY (INHALATION) | 90 mg | ||
| lactose | LACTOSE | J2B2A4N98G | CREAM / VAGINAL | 3 %w/w | ||
| lactose | LACTOSE | J2B2A4N98G | CAPSULE, EXTENDED RELEASE / ORAL | 120 mg | ||
| lactose | LACTOSE | J2B2A4N98G | CAPSULE, COATED, EXTENDED RELEASE / ORAL | NA | ||
| lactose | LACTOSE | J2B2A4N98G | TABLET, FILM COATED, EXTENDED RELEASE / ORAL | 620 mg | ||
| lactose | LACTOSE | J2B2A4N98G | INJECTION, POWDER, FOR SOLUTION / SUBCUTANEOUS | 133 mg | ||
| lactose | LACTOSE | J2B2A4N98G | TABLET, COATED / ORAL | 332.05 mg | ||
| lactose | LACTOSE | J2B2A4N98G | TABLET, SUGAR COATED / ORAL | NA | ||
| lactose | LACTOSE | J2B2A4N98G | INJECTION / INTRAVENOUS | 203.5 mg | ||
| lactose | LACTOSE | J2B2A4N98G | TABLET, EFFERVESCENT / ORAL | 96.5 mg | ||
| lactose | LACTOSE | J2B2A4N98G | OINTMENT / TOPICAL | NA |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| 9d8cfc6f-ce07-4da3-9b51-2cceff9115c3 | 124a7f43-181b-4b00-948d-f7bcceeb77c3 | 2009-10-13 | Warnings | 9d8cfc6f-ce07-4da3-9b51-2cceff9115c3 124a7f43-181b-4b00-948d-f7bcceeb77c3 |
Adverse event summaries are temporarily unavailable. Other product information remains available.